Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 15/20 | 0.42 |
| ▸ | CTSS | P25774 | 13/20 | 0.42 |
| ▸ | CTSK | P43235 | 12/20 | 0.42 |
| ▸ | CTSB | P07858 | 12/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2156402 | 0.88 | CTSL (0.48) | CTSLCTSSCTSKCTSB | |
| SCHEMBL2156596 | 0.87 | CTSL (0.51) | CTSLCTSSCTSKCTSBNPSR1 | |
| SCHEMBL2156545 | 0.81 | CTSL (0.50) | CTSLCTSSCTSKCTSB | |
| SCHEMBL2156630 | 0.81 | CTSL (0.50) | CTSLCTSSCTSKCTSB | |
| SCHEMBL6364137 | 0.81 | CTSL (0.37) | CTSLCTSSCTSKCTSB | |
| SCHEMBL5672363 | 0.78 | CTSL (0.39) | CTSLCTSSCTSKCTSB | |
| SCHEMBL2157314 | 0.77 | CTSL (0.39) | CTSLCTSSCTSKCTSB | |
| SCHEMBL2156663 | 0.75 | CTSL (0.46) | CTSLCTSSCTSKCTSB | |
| SCHEMBL2156748 | 0.74 | CTSL (0.42) | CTSLCTSSCTSKCTSB | |
| SCHEMBL2155658 | 0.74 | CTSL (0.49) | CTSLCTSSCTSKCTSBGPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050240023-A1 | N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; osteoporosis and other bone loss disorders | MERCK CANADA INC. (CA) | 2005-10-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050240023-A1 | N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; osteoporosis and other bone loss disorders | CTSE, CTSS, CTSB | CTSL 7/4885CTSS 2/4885CTSK 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.